Traders Buy High Volume of Tempest Therapeutics Call Options (NASDAQ:TPST)

Tempest Therapeutics, Inc. (NASDAQ:TPST) was the target of some unusual options trading on Wednesday. Investors purchased 2,888 call options on the stock. This represents an increase of approximately 1,069% compared to the typical volume of 247 call options.

Insider Activity

In other news, major shareholder Versant Venture Capital Vi, L. sold 387,999 shares of Tempest Therapeutics stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $1.10, for a total value of $426,798.90. Following the completion of the transaction, the insider now owns 209,941 shares in the company, valued at approximately $230,935.10. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 3.27% of the company’s stock.

Institutional Investors Weigh In On Tempest Therapeutics

An institutional investor recently raised its position in Tempest Therapeutics stock. Virtu Financial LLC grew its stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) by 69.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 28,574 shares of the company’s stock after purchasing an additional 11,689 shares during the period. Virtu Financial LLC owned approximately 0.13% of Tempest Therapeutics worth $112,000 at the end of the most recent reporting period. 22.52% of the stock is owned by institutional investors.

Tempest Therapeutics Price Performance

Shares of NASDAQ TPST opened at $1.11 on Thursday. The company has a current ratio of 2.17, a quick ratio of 2.17 and a debt-to-equity ratio of 0.12. Tempest Therapeutics has a twelve month low of $0.92 and a twelve month high of $9.00. The stock has a 50 day moving average of $1.31 and a two-hundred day moving average of $2.34. The stock has a market cap of $24.66 million, a P/E ratio of -0.65 and a beta of -1.86.

Tempest Therapeutics (NASDAQ:TPST) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.05. On average, research analysts forecast that Tempest Therapeutics will post -1.43 earnings per share for the current year.

Analyst Ratings Changes

TPST has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $47.00 target price on shares of Tempest Therapeutics in a research note on Thursday, October 10th. Piper Sandler restated an “overweight” rating and set a $8.00 target price on shares of Tempest Therapeutics in a research note on Friday, June 21st. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Tempest Therapeutics presently has a consensus rating of “Buy” and an average price target of $20.75.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.